These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 23989299)

  • 1. Pregabalin abuse among opiate addicted patients.
    Grosshans M; Lemenager T; Vollmert C; Kaemmerer N; Schreiner R; Mutschler J; Wagner X; Kiefer F; Hermann D
    Eur J Clin Pharmacol; 2013 Dec; 69(12):2021-5. PubMed ID: 23989299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pregabalin Abuse amongst Opioid Substitution Treatment Patients.
    McNamara S; Stokes S; Kilduff R; Shine A
    Ir Med J; 2015; 108(10):309-10. PubMed ID: 26817289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A signal for an abuse liability for pregabalin--results from the Swedish spontaneous adverse drug reaction reporting system.
    Schwan S; Sundström A; Stjernberg E; Hallberg E; Hallberg P
    Eur J Clin Pharmacol; 2010 Sep; 66(9):947-53. PubMed ID: 20563568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders.
    Tassone DM; Boyce E; Guyer J; Nuzum D
    Clin Ther; 2007 Jan; 29(1):26-48. PubMed ID: 17379045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential for pregabalin abuse or diversion after past drug-seeking behavior.
    Filipetto FA; Zipp CP; Coren JS
    J Am Osteopath Assoc; 2010 Oct; 110(10):605-7. PubMed ID: 21068226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urine drug testing of chronic pain patients. IV. prevalence of gabapentin and pregabalin.
    Heltsley R; Depriest A; Black DL; Robert T; Caplan YH; Cone EJ
    J Anal Toxicol; 2011 Jul; 35(6):357-9. PubMed ID: 21740692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pregabalin for the reduction of opiate withdrawal symptoms].
    Kämmerer N; Lemenager T; Grosshans M; Kiefer F; Hermann D
    Psychiatr Prax; 2012 Oct; 39(7):351-2. PubMed ID: 22689280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pregabalin--a drug with abuse potential?].
    Skopp G; Zimmer G
    Arch Kriminol; 2012; 229(1-2):44-54. PubMed ID: 22448469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pregabalin misuse in methadone maintenance treatment patients in Israel: Prevalence and risk factors.
    Sason A; Adelson M; Schreiber S; Peles E
    Drug Alcohol Depend; 2018 Aug; 189():8-11. PubMed ID: 29857329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pregabalin abuse and dependence in Germany: results from a database query.
    Gahr M; Freudenmann RW; Hiemke C; Kölle MA; Schönfeldt-Lecuona C
    Eur J Clin Pharmacol; 2013 Jun; 69(6):1335-42. PubMed ID: 23292158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pregabalin dependence: a case report.
    Halaby A; Kassm SA; Naja WJ
    Curr Drug Saf; 2015; 10(2):184-6. PubMed ID: 25336156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pain of pregabalin prescribing in prisons.
    Bicknell M
    Br J Gen Pract; 2013 Aug; 63(613):405. PubMed ID: 23972175
    [No Abstract]   [Full Text] [Related]  

  • 13. GC-MS/MS detects potential pregabalin abuse in susceptible subjects' hair.
    Ianni F; Aroni K; Gili A; Sardella R; Bacci M; Lancia M; Natalini B; Gambelunghe C
    Drug Test Anal; 2018 Jun; 10(6):968-976. PubMed ID: 29214743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensive monitoring of pregabalin: results from an observational, Web-based, prospective cohort study in the Netherlands using patients as a source of information.
    Härmark L; van Puijenbroek E; Straus S; van Grootheest K
    Drug Saf; 2011 Mar; 34(3):221-31. PubMed ID: 21332246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pregabalin in clinical psychiatry and addiction: pros and cons.
    Martinotti G
    Expert Opin Investig Drugs; 2012 Sep; 21(9):1243-5. PubMed ID: 22725618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with pregabalin dispensing at higher than the approved maximum dose.
    Bodén R; Wettermark B; Brandt L; Kieler H
    Eur J Clin Pharmacol; 2014 Feb; 70(2):197-204. PubMed ID: 24141597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics of pregabalin in healthy volunteers.
    Bockbrader HN; Radulovic LL; Posvar EL; Strand JC; Alvey CW; Busch JA; Randinitis EJ; Corrigan BW; Haig GM; Boyd RA; Wesche DL
    J Clin Pharmacol; 2010 Aug; 50(8):941-50. PubMed ID: 20147618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential of pregabalin in neurology, psychiatry and addiction: a qualitative overview.
    Martinotti G; Lupi M; Sarchione F; Santacroce R; Salone A; De Berardis D; Serroni N; Cavuto M; Signorelli M; Aguglia E; Valchera A; Iasevoli F; Di Giannantonio M
    Curr Pharm Des; 2013; 19(35):6367-74. PubMed ID: 23782139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
    Guay DR
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):274-87. PubMed ID: 16503325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subjective, psychomotor, and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteers.
    Zacny JP; Paice JA; Coalson DW
    Pharmacol Biochem Behav; 2012 Jan; 100(3):560-5. PubMed ID: 22085697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.